Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients

Russo, Giuseppina T.; Labate, Agata; Giandalia, Annalisa; Romeo, Elisabetta L.; Villari, Provvidenza; Alibrandi, Angela; Perdichizzi, Giuseppa; Cucinotta, Domenico

doi:10.1007/s40618-014-0163-9

Cited by 34 publications

(27 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than half of the 43 full-text journal articles [28–70] had a study design which involved analyses of data that were previously collected from patient medical record/chart review from hospitals, or databases (53.5%; N = 23) [28, 30–33, 37, 39, 40, 43, 44, 46, 49–51, 54–58, 61, 62, 65, 70]. The majority of the studies assessed the clinical effectiveness of liraglutide without an active comparator (81.4%; N = 35) [28, 29, 31, 34, 36–39, 41–49, 51–55, 57, 60–64, 66–71].…”

Section: Resultsmentioning

confidence: 99%

“…The most frequently observed follow-up duration from these publications was ≥12 months (46.5%; N = 20) [28–47], followed by 6–12 months (34.9%; N = 15) [48–62], and <6 months (18.6%; N = 8) [63–70]. Real-world studies frequently reported data on the effect of liraglutide from outpatient settings (30.2%; N = 13) [34, 39, 40, 42–44, 49, 55, 58, 60, 61, 66, 67]. The geographical scope of the review included studies from Europe ( N = 24), the USA ( N = 5), and Asia–Pacific ( N = 14; see supplementary file 2).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review

Ostawal¹,

Mocevic

Kragh

et al. 2016

Diabetes Ther

View full text Add to dashboard Cite

IntroductionIn clinical trials, liraglutide has proven to be an effective drug for the treatment of type 2 diabetes mellitus (T2DM). The real-world effectiveness of liraglutide has been investigated in numerous studies. The aim of this systematic literature review is to collate evidence on the real-world clinical effectiveness of liraglutide.MethodsA review of publications from Medline, EMBASE, the Cochrane Library, and conference proceedings was conducted to identify observational studies that assessed the clinical effectiveness of liraglutide in real-world clinical practice. This review was conducted according to the National Institute of Health and Care Excellence (NICE) guidance. No language or time limits were applied, except to the conference proceedings (2013–2015). Endpoints for data extraction were decided a priori. Study quality appraisal was done for full-text journal articles.ResultsOf 124 publications included in the review, 43 were full-text articles. Liraglutide significantly reduces glycated hemoglobin (HbA1c) within 6 months of initiating treatment (mean change in HbA1c from baseline: −0.9% to −2.2%; HbA1c <7.0%: 29.5–65.0%). The NICE composite endpoint (HbA1c reduction ≥1% and weight reduction ≥3%) was met in 16.9–47.0% of patients with liraglutide treatment. Liraglutide therapy led to a mean change in absolute weight from baseline of −1.3 to −8.65 kg. Liraglutide treatment was well tolerated in patients with T2DM. The rate of occurrence of hypoglycemia with liraglutide monotherapy was ≤0.8%. Hypoglycemia was more common in patients taking antidiabetic medications (0.0–15.2%) together with liraglutide. The beneficial glycemic and weight effect of liraglutide therapy in patients with T2DM was maintained for at least 12 months.ConclusionEvidence from observational studies reflecting real-world clinical practice demonstrates that liraglutide therapy improves glycemic control with a low risk of hypoglycemia, and is associated with significant weight loss in patients with T2DM. These observations are consistent with clinical trial findings.FundingNovo Nordisk A/S, Søborg, Denmark.Electronic supplementary materialThe online version of this article (doi:10.1007/s13300-016-0180-0) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review

Ostawal¹,

Mocevic

Kragh

et al. 2016

Diabetes Ther

View full text Add to dashboard Cite

show abstract

“…VAI has showed a strong independent association with cardiometabolic risk [13] . Additionally, VAI also increased cardiometabolic risk in type 2 diabetes and was therefore significantly decreased after 12 month's intervention with medicine [38] . A Tehran study conducted by Bozorgmanesh et al [18] reported that VAI could be a prognostic tool for predicting the risk of type 2 diabetes, but is unlikely to be superior to WHtR.…”

Section: Discussionmentioning

confidence: 97%

Visceral Adiposity Index Is Associated with Pre-Diabetes and Type 2 Diabetes Mellitus in Chinese Adults Aged 20-50

Liu¹,

Ma²,

Liu

et al. 2016

Ann Nutr Metab

View full text Add to dashboard Cite

Background/Aims: Diabetes mellitus and pre-diabetes are closely associated with visceral obesity. Visceral adiposity index (VAI) is a novel sex-specific index, indirectly expressing visceral adipose function. Our aim was to determine the associations of VAI with dysglycemia (the combination of diabetes and pre-diabetes) and to compare the predictive ability for dysglycemia between VAI and traditional obesity indices. Methods: We performed a cross-sectional analysis of the data of 2,754 Chinese community-dwelling people who participated in the health checkup. Sex-specific VAI tertile cut-off points were used as follows: 1.70, 2.77 in males and 0.98, 1.75 in females. Binary logistic regression models were performed to estimate the association of the higher values of all the obesity indices with pre-diabetes and diabetes. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve was applied to compare the predictive potential for dysglycemia among the obesity indices. Results: VAI was the only index significantly associated with both pre-diabetes and diabetes in both sexes after adjusting for potential confounders. The results of ROC analysis and AUC showed that VAI possessed the largest AUC, followed by other obesity indices. Conclusions: Higher VAI values are positively associated with the presence of pre-diabetes and diabetes in Chinese adults.

show abstract

“…Results demonstrated that treatment with liraglutide was associated with significantly reduced all major CVD risk factors and reduced cardiometabolic risk evaluated by the Visceral Adiposity Index [89].…”

Section: Cardiovascular Safetymentioning

confidence: 99%

Liraglutide for Type 2 diabetes and obesity: a 2015 update

Iepsen

Torekov

Holst

2015

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Subcutaneous liraglutide (Victoza(®), Novo Nordisk) was approved for the treatment of Type 2 diabetes mellitus (T2DM) in Europe in 2009 and in the USA in 2010. In December 2014, liraglutide 3.0 mg was approved by the Food and Drug Administration (FDA) and in March 2015 by the European Medicines Agency (EMA) for the treatment of chronic weight management under the brand name Saxenda(®) Novo Nordisk. Liraglutide causes a glucose-dependent increase in insulin secretion, decreases glucagon secretion and promotes weight loss by inhibiting appetite. Liraglutide probably induces satiety through activation of different areas in the hind brain and possibly by preserving free leptin levels. Recently, liraglutide has been suggested to protect against prediabetes and seems to prevent bone loss by increasing bone formation following diet-induced weight loss in obesity. This article not only covers the major clinical trials evaluating the effects of liraglutide in obesity and T2DM but also provides novel insights into the pharmacological mechanisms of liraglutide.

show abstract

Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients

Abstract: In conclusion, 12-month treatment with liraglutide in add-on to on-going hypoglycemic therapy significantly ameliorates all major CVD risk factors and reduces cardiometabolic risk, as estimated by VAI values.

Cited by 34 publications

References 32 publications

Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review

Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review

Visceral Adiposity Index Is Associated with Pre-Diabetes and Type 2 Diabetes Mellitus in Chinese Adults Aged 20-50

Liraglutide for Type 2 diabetes and obesity: a 2015 update

Contact Info

Product

Resources

About